On 13 May 2011, orphan designation (EU/3/11/865) was granted by the European Commission to ORS Oxford Ltd, United Kingdom, for 9-cis-retinyl acetate for the treatment of retinitis pigmentosa. The sponsorship was transferred to QLT Ophthalmics (UK), Ltd, United Kingdom, in November 2011.
The sponsorship was transferred to Granzer Regulatory Consulting & Services, Germany in May 2019.
|Disease / condition||
Treatment of retinitis pigmentosa
|Date of first decision||
|EU designation number||
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;